Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers identified PDE5 inhibitors, like Viagra, as potential treatments for glioblastoma multiforme and other rare cancers. The study suggests these drugs may increase permeability to improve drug delivery to brain tumors.
Researchers found that adding trastuzumab to chemotherapy regimen for women with uterine serous carcinoma significantly increased progression-free survival time, from an average of eight months to 12.6 months. The treatment showed promise in reducing tumor growth and improving overall survival.
Researchers aim to eradicate chronic lymphocytic leukemia (CLL) by targeting specific cancer cells. The team has discovered a binding site on CLL lymphocytes that pulls antibodies into the cells in minutes, allowing for more effective treatments.
Researchers have discovered a new class of drug that targets treatment-resistant cancers by inhibiting the action of enzyme CDK7. Early lab-based tests showed minimal side effects and successful suppression of tumour growth in various cancer types.
A University of North Carolina-led study has found that physicians who received payments from pharmaceutical companies were more likely to prescribe those companies' drugs for two cancer types. The study analyzed prescriptions for Medicare patients with metastatic renal cell cancer and chronic myeloid leukemia, finding a significant as...
Researchers used machine learning to classify abnormal protein activity in tumors, identifying potential 'hidden responders' who may benefit from specific therapies. The study combined genetic data with machine learning approaches to predict response to inhibitors affecting cancer cells with overactive Ras signaling.
Researchers from the University of Cambridge identified key anti-cancer drugs that could be used to treat transmissible cancers in Tasmanian devils. The study found that the two types of cancer are similar and likely arose due to the devils' susceptibility to developing these diseases.
A study found that only 16% of respondents were aware of drug shortages, and those with a personal history of cancer were more likely to be aware. Most respondents wanted to be informed about substitution due to shortages and would transfer care to avoid major differences in efficacy.
A promising class of drugs, known as CD40 monoclonal antibodies, could be the spark needed to light the fire in the immune system of patients who don't respond to cancer immunotherapies. These drugs activate antigen-presenting cells to prime tumor-specific T cell responses.
Researchers identified two transmissible cancers in Tasmanian devils, suggesting a genetic problem with cell regulation that increases disease risk. The effective drugs discovered may also play a role in wound repair pathways, potentially linked to the devils' frequent facial injuries.
Researchers found all frailty scores associated with future mortality, and some linked to cardiovascular disease but none to cancer. Certain scores outperform others for all-cause mortality and cardiovascular health outcomes.
The PDX Finder is a free global portal for cancer models, offering over 1900 clinically relevant models from multiple repositories. Researchers can search and submit their own models to accelerate collaborative research and time-saving.
A clinical trial has shown that a combination of checkpoint inhibitors and an immune stimulation drug can control the progression of non-small cell lung cancer. The treatment was administered in an outpatient setting and demonstrated significant prolonged survival in patients.
Researchers from Eindhoven University of Technology developed a cheaper production method for the cancer drug Z-endoxifen, using a paper filter purification process inspired by filtering coffee. This approach reduces production costs to 1,000 times lower than the previous method.
Researchers created patient-specific bladder cancer organoids that mimic actual tumors, allowing for testing of multiple drugs and predicting individual response to treatment. The use of these personalized models may improve understanding of the genomics of bladder cancer and develop new therapies.
The Cancer Genome Atlas project has identified 300 genes that drive tumor growth and found that just over half of tumors carry genetic mutations targetable by existing therapies. The research provides unprecedented understanding of cancer's genetic basis, enabling better-informed clinical trials and future treatments.
The Translational Genomics Research Institute (TGen) will receive $450,000 to fund a clinical trial for a newly developed ovarian cancer drug treatment, thanks to Colleen's Dream Foundation. The foundation has funded TGen in the past and has awarded over $1.2 million in grants to 27 institutions.
Researchers at Cold Spring Harbor Laboratory discovered that cancer cells lacking tumor-suppressor protein PTEN are vulnerable to mitochondrial inhibitors, which induce them to consume glucose and quickly run out of energy. This finding suggests that such drugs could eliminate cancer cells while leaving healthy cells intact.
A combination of EGFR and TNF inhibitors effectively blocks cancer's escape route, making it sensitive to treatment. The two-drug strategy has the potential to work for all non-small cell lung cancers, offering a new hope for patients.
Researchers identified nearly 200 mutations in non-coding DNA that play a functional role in cancer, providing potential molecularly targeted therapeutics. These mutations could represent new targets for cancer drugs and may help explain the diversity of genetic mutations in tumors.
Researchers have engineered brewer's yeast to produce noscapine, a potential cancer drug with fewer side effects than conventional chemotherapy. The engineered yeast strain produced 2.2 mg/L noscapine after optimization, paving the way for large-scale commercial production.
Researchers at Massachusetts General Hospital report promising preclinical results against uniformly fatal tumor, finding that combining two cancer immunotherapy drugs significantly prolongs survival time. The treatment changes a population of immunosuppressive T cells into a type that could enhance an antitumor immune response.
Researchers successfully treat KRAS-driven lung cancer by targeting insulin and IGF-1 signaling, identifying metabolic vulnerabilities. The study shows that completely blocking the pathway can slow tumor growth, but a second step is needed to fully suppress it.
A recent study found that cancer survivors were more likely to be insured, yet still reported greater challenges in accessing and affording healthcare compared to adults without cancer. The proportion of cancer survivors experiencing these issues decreased over time since the Affordable Care Act (ACA) was signed into law.
Larotrectinib, a new pediatric cancer drug targeting the TRK gene fusion, showed an unprecedented 93 percent response rate in patients tested. The drug has been effective in treating rare pediatric cancers such as infantile fibrosarcoma and papillary thyroid cancer.
A study published in the Journal of Clinical Oncology found that taking a standard prostate cancer drug with food can boost its impact and lower costs. By decreasing the daily dose, preventing digestive issues, and cutting costs by 75 percent, patients could save up to $300,000 per month.
Researchers at the University of Johannesburg have discovered a new family of economical silver-based complexes that show very promising results against various human cancers. These complexes, such as UJ3, are selective and have low toxicity, making them a potential alternative to existing chemotherapy drugs.
Scientists at Michigan State University have discovered a promising new drug that targets the c-Myc gene, which is linked to obesity and various cancers. The drug, I-BET-762, delays the development of existing cancers by inhibiting critical proteins involved in cancer cell growth.
A recent study found that receptivity to e-cigarette advertising significantly increased the odds of 12-21 year-olds who have never smoked trying cigarette smoking within a year. This association was independent of receptivity to cigarette advertising.
Researchers found that changing the scheduling of drug administration can improve outcomes in mouse models of melanoma, leading to more complete responses. A combination of MEK inhibitor given continuously with intermittent CDK4/6 inhibitor was the most effective schedule in mice.
A meta-analysis by Case Western Reserve University researcher Nathan Berger reveals that obesity increases risk of 13 different cancers in young adults, with certain cancers now reported in people under 50. Obesity can alter cellular mechanisms promoting cancer and increase cancer rates as it rises among younger demographics.
A Singapore-led team of Asian cancer researchers has won the prestigious AACR Team Science Award for their groundbreaking work on cancers prevalent in Asia. The team's research has identified new genes and pathways, translated findings into clinical trials, and informed government policies.
A new antimalarial drug delivery system using MCM-41 has been developed, demonstrating a long release time of one week or longer and increasing treatment efficiency by 20 and 240 times compared to traditional medications.
Researchers identified new genetic mutations in cancer cells that promote survival and resistance to treatment. The study found that no two cancers were genetically identical, even among those with similar characteristics.
Researchers at Houston Methodist have identified a compound that prevents breast cancer cells from spreading to the brain. Edelfosine, an investigational leukemia treatment, has been shown to stop cancer stem cells from growing once they reach the brain. This finding offers new hope for treating metastatic brain disease.
A new study using Medicare claims data found that finasteride significantly reduces prostate cancer risk over a period of 16 years, with a 21% decrease in risk compared to those on a placebo. This long-term benefit is twice as long as previously recorded.
Researchers established two new adrenal cancer cell lines and mouse models to test novel treatments, identifying PBK as a key target. A patient treated with pembrolizumab showed remarkable response with 77% tumor reduction, while a humanized mouse model also responded to the immunotherapy.
A new study by Dartmouth Health suggests that e-cigarette use may be more harmful than beneficial, particularly among adolescents and young adults. The research found that e-cigarettes could lead to over 1.5 million years of life lost due to increased smoking rates among youth.
Researchers have created BN/Ag hybrid nanomaterials that demonstrate effectiveness as catalysts, antibacterial agents, and drug delivery systems for treating oncological diseases. The hybrids show high potential for cancer therapy and water disinfection, offering a new approach to combatting these threats.
Moffitt researchers used single-cell imaging and mathematical modeling to determine the most important drug characteristics for efficient uptake by tumor cells. They found that drugs with different diffusion rates and concentrations bind effectively to cells based on their distance from blood vessels and density of drug receptors.
Researchers have identified 110 genes linked to an increased risk of breast cancer, including 32 genes related to survival rates. The study uses a genetic technique to analyze DNA regions and identify specific genes involved in raising a woman's risk.
Researchers discovered that inhibiting autophagy with the help of FOXO3a molecule can push cancer cells into apoptosis. The study found that combining autophagy inhibition with a drug called Nutlin increases PUMA production, leading to cell death.
A study found that ACE-inhibitors and beta blockers can reduce the risk of heart damage in women receiving anthracycline-based chemotherapy alongside trastuzumab. However, these medications were not effective for those without a history of anthracycline exposure.
Researchers are testing a new combination of cirmtuzumab and ibrutinib to eradicate leukemias and other blood cancers. The trial aims to determine the safety and effectiveness of the duo's treatment, which could potentially lead to complete remissions without continuous therapy.
Scientists at Cold Spring Harbor Laboratory have discovered a way to rein in an overactive protein that drives some aggressive leukemias. The team's CRISPR-based system identifies two enzymes, LKB1 and salt-inducible kinase, as critical for the survival of certain AML cells.
Researchers found a 'stop sign' protein that prevents healthy cells from sorting material, leading to unregulated growth in cancerous cells. This discovery opens the door to designing drugs that block PIP-stop formation by kinase enzymes, targeting difficult-to-treat cancers.
A recent study published in The BMJ questioned the underlying evidence for current US cancer treatment guidelines. Researchers found that these guidelines often rely on low-quality or no evidence at all. The study highlights concerns about the justification of costly and toxic cancer drugs based on weak evidence.
A new slow-release hydrogel has been developed to aid immunotherapy for cancer, providing a continuous dose of immunotherapy drugs to activate the immune system. The hydrogel, called STINGel, was tested in lab cultures and in vivo trials, showing promise in killing cancer cells and preventing further implantation of cancer cells.
Scientists at Greehey Children's Cancer Research Institute have found a new mechanism by which BRCA1 can be rendered dysfunctional in Ewing sarcoma. The study reveals that the mutant oncogene produced by the fusion oncogene traps BRCA1, preventing it from repairing genetic damage.
Research from the University of Pittsburgh School of Medicine discovered that preventing T-cell exhaustion with targeted therapies enhances immunotherapy outcomes. Activating a protein called 41BB on the surface of T-cells improves energy reserves and prolongs their ability to attack cancer cells.
Researchers found that multiple small differences, rather than a single factor, explain the large variation in how people respond to drugs. The study used systems biology and metabolomics techniques to analyze protein and metabolite concentrations in cell culture experiments.
Biochemists have made a discovery that sheds light on the molecular machinery that allows some cells to wiggle their way through tissues. The researchers identified two locations on Arp2/3 where an activator protein touches, promoting cell motility and potentially leading to new opportunities for cancer treatment.
Researchers at Purdue University have created a lifelike cancer environment using polymer to better understand how drugs can stop its course. The 3D jet writer device produces polymer microtissues with pore sizes large enough for cells to enter, enabling the simulation of metastasis in mice.
The American Academy of Otolaryngology has released an updated guideline for treating hoarseness, recommending earlier evaluation by an otolaryngologist and discouraging the use of unnecessary medications. The guidelines aim to reduce variation in care and improve patient outcomes.
A new blood test detects circulating tumour DNA to predict if the breast cancer drug palbociclib is working, allowing for earlier treatment adjustments. The test was found to be effective in identifying patients who are not responding well to the treatment.
Researchers at USC Michelson Center successfully utilize a new metal detection technique for studying cancer cells. By imaging metal-tagged antibodies on biopsies from a patient with metastatic prostate cancer, scientists can identify and characterize cancer cells in a blood sample after it is placed on a slide.
Researchers at NIH have cured mice with Chuvash polycythemia, a life-threatening disorder that involves overproduction of red blood cells. The study suggests that Tempol or a similar drug may treat polycythemias in humans, such as mountain sickness.
In three clinical trials, larotrectinib demonstrated a 75% overall response rate in patients with TRK fusion genes, with 86% continuing treatment or undergoing curative surgery. This study marks a new paradigm in cancer drug development, defining cancers by molecular changes rather than site of occurrence.
A phase I clinical trial has shown some promise for an investigational compound designed to block a hyperactive cell growth signal in advanced melanoma and other cancers. Three patients experienced partial responses to the treatment, similar to response rates seen with other treatments such as MEK inhibitors.
The researchers developed a new class of bifunctional immunotherapeutic agents called Y-traps, which can target and disable multiple immune suppressive molecules. These Y-traps were found to be effective in inhibiting tumor growth and activating antitumor immunity, even against cancers that do not respond to existing immunotherapies.